Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05040568 · ClinicalTrials.gov registry record · Phase 1
A Phase IB Study OF Immunotherapy With EX Vivo Pre-activated AND Expanded Cb-nk Cells IN Combination With Cetuximab, IN Colorectal Cancer Patients With Minimal Residual Disease (MRD)
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT05040568: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT05040568 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05040568, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
A study of immunotherapy with expanded CB-NK cells in combination with cetuximab, to evaluate activity against minimal residual disease in patients with colon cancer that have completed adjuvant treatment but are positive for ctDNA
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine phosphate
- DRUG Cetuximab
- DRUG Expanded CB-NK cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-02-28 |
| Est. Completion | 2026-01-15 |
| Phase | Phase 1 |
What the finished NCT05040568 record still lists
NCT05040568 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT05040568 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05040568 about?
NCT05040568 is a clinical study titled "A Phase IB Study OF Immunotherapy With EX Vivo Pre-activated AND Expanded Cb-nk Cells IN Combination With Cetuximab, IN Colorectal Cancer Patients With Minimal Residual Disease (MRD)". A study of immunotherapy with expanded CB-NK cells in combination with cetuximab, to evaluate activity against minimal residual disease in patients with colon cancer that have completed adjuvant treatment but are positive for ctDNA
What is the current status of trial NCT05040568?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-02-28. Estimated completion is 2026-01-15.
What interventions are being tested in trial NCT05040568?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine phosphate (DRUG), Cetuximab (DRUG), Expanded CB-NK cells (DRUG).
Who is sponsoring clinical trial NCT05040568?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05040568's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI